6973 results for
Refine Your Search
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Dr. Mendel Goldfinger and collaborators of Einstein have shown in a preliminary trial that weekly low dose decitabine plus one a week venetoclax is hi…
Mendel Goldfinger
Coming Soon.
Uncovering MGA-driven epigenetic reprogramming in Richter's syndrome
Richter’s syndrome (RS) is a critical complication of chronic lymphocytic leukemia. RS patients are refractory to most existing therapies and show a m…
Ramon Massoni-Badosa
Ramon Massoni-Badosa, PhD is a graduate of Pompeu Fabra University, Barcelona in 2023, and his PhD focused on applying single-cell genomics technologi…
Investigating the dependency for protein synthesis in Venetoclax/Azacitidine-resistant acute myeloid leukemia
Relapsed and/or refractory acute myeloid leukemia (AML) display resistance to Venetoclax and Azacitidine (Ven/Aza) with approximately one third of pat…
Ana Vujovic
Ana Vujovic is a postdoctoral research fellow at the University of Colorado Anschutz Medical Campus. She completed her PhD under the mentorship of Dr.
TCR-like CARs targeting GvL mHAgs for the treatment of post-transplant AML relapse
AML recurrence is a devastating event after allo-HCT. I hypothesize that it could be counteracted through targeting of leukemia-restricted mHAgs via T…
Nicoletta Cieri
Nicoletta Cieri is a Postdoctoral Research Fellow at Dana-Farber Cancer Institute. Before joining DFCI, Nicoletta obtained her MD degree summa cum lau…
Novel CD7 CAR T-cells for refractory T-cell malignancies affecting pediatric and AYA patients
T-cell leukemias and lymphomas have devastating outcomes if they recur after or don’t respond to standard treatment, with the only hope of cure being …
Rayne Rouce
Dr. Rouce is a pediatric oncologist and physician scientist whose clinical research focuses on difficult-to-treat blood cancers, specifically how to h…
A phase 2 trial of EO2463, a novel microbial-derived peptide therapeutic vaccine, as monotherapy, and in combination with lenalidomide and rituximab, for treatment of patients with indolent NHL
In October 2023, LLS made an equity investment in Enterome to "support the ongoing Phase 2 SIDNEY study of EO2463 in indolent non-Hodgkin B-cell lymph…
Development of cellular therapy for CMML and the Immune landscape of response and resistance
We will test the efficacy of CAR T cell therapy for CMML. We will modify the tumor microenvironment to enhance their efficacy. and we will upscale CAR…
Huda Salman
My clinical and research interest is to develop therapies that enhance the immune system to fight blood cancer. In my laboratory, we have developed CA…
Sam Butterworth
Sam Butterworth joined the University of Manchester as a Senior Lecturer in Medicinal Chemistry in November 2016. Prior to this he worked at the Unive…
Development of peptide-drug conjugates for the treatment of Chronic Myelomonocytic Leukaemia (CMML)
We are aiming to bring a new treatment option to patients with chronic myelomonocytic leukemia (CMML) by utilising CCL2-drug conjugates that specifica…
CLL-1 CAR-T cells and trametinib for the treatment of Ras-mutated CMML and JMML
hypothesize that demonstrating activity of CLL-1 CAR-T (CLL1CART) cell therapy with or without trametinib in pre-clinical models of chronic myelomonoc…
Elliot Stieglitz
Dr. Elliot Stieglitz is a physician-scientist at the University of California, San Francisco whose research focuses on children diagnosed with juvenil…
Eric Padron
Eric Padron, MD is an Associate Member and Scientific Director of the Department of Hematology at Moffitt Cancer Center (MCC). He completed a hematolo…
Advancing the therapeutic landscape for Chronic Myelomonocytic Leukemia (CMML)
CMML is a universally lethal blood cancer characterized by increased monocytes (a type of white blood cell) in the peripheral blood and abnormal appea…
A phase 1 study of VIPER-101, a CD5-edited dual population chimeric antigen receptor cell therapy, to enhance immunotherapy against T-cell non-Hodgkin lymphoma
In October 2023, LLS made an equity investment in Vittoria to "Support Clinical Development of VIPER-101, a CAR-T Cell Therapy for T-cell lymphomas."V…
Vittoria Biotherapeutics
Vittoria Biotherapeutics is developing novel CAR-T cell therapies that transcend the limitations of current cell therapies.
Resources for Blood Cancer Caregivers
Get fast access to support materials, financial assistance, booklets, podcasts, videos, and other free resources to support you throughout your loved …
Our impact on blood cancer research
Research: Grants
Research: TAP